In a Perspective published today in the inaugural issue of Brain Health (https://doi.org/10.61373/bh026p.0006), an international team of researchers claims that human microplastic burden has crossed the threshold from an environmental problem to a brain health emergency. This article is published to coincide with the launch of Brain Health, Genomic Press’ new peer-reviewed journal dedicated to the science of brain resilience across the lifespan.
This Perspective integrates evidence across three areas that until recently were kept in separate scientific silos. Brain tissue from deceased individuals sampled from the 2016-2024 cohort and analyzed by Nihart et al. at the University of New Mexico contained microplastic concentrations 7 to 30 times higher than corresponding liver and kidney samples. Cumulative tissue burden increased approximately 50% over that 8-year period. Donors diagnosed with dementia bore the heaviest burden. Polyethylene was predominant and mainly present as nanoscale fragment-like debris.
The cardiovascular evidence is equally striking. Marfella et al. worked with patients undergoing carotid endarterectomy to identify microplastics and nanoplastics within atherosclerotic plaques. Patients whose plaque tests were positive for these particles had an approximately four-fold increased combined risk of myocardial infarction, stroke, and death over a 34-week follow-up period. As a new Perspective points out, this is as much a finding in the brain as it is a finding in the heart, because stroke is a result of the brain.
How do these particles reach the brain in the first place? Animal data is now filling the gap. Polystyrene nanoparticles administered orally to mice were shown by Kopatz et al. to cross the blood-brain barrier within 2 hours of exposure, with the biomolecular corona acquired during transit serving as a passport for entry. Large particles do not intersect. Nanoscale particles do.
“We are focusing on the organs that have the highest measured concentrations of microplastics and meet the most important clinical endpoints in medicine,” says Perspective’s lead author, Julio Ricinio, Ph.D., publisher and CEO of Genomic Press.
Cognition, mood, stroke, and dementia. Treating this as a peripheral environmental problem becomes difficult to defend when the peripheral organs involved carry fewer pollutants than the central organs. ”
Dr. Julio Licinio, Publisher and CEO, Genomic Press
This vision also brings to the fore ultra-processed foods, a delivery vehicle that operates on a population scale. Ultra-processed foods, Group 4 of the NOVA classification, currently provide more than half of the United States’ caloric intake. They are also high-throughput vectors of microplastic exposure through package migration during heating and storage, mechanical wear during industrial processing, and downstream contamination. Consumption of ultra-processed foods, independent of microplastic content, appears to be associated with depression, anxiety, cognitive decline, stroke, and dementia in a large prospective cohort. A meta-analysis of 385,541 participants found that those who ate the highest amounts of ultra-processed foods had a 53 percent increased chance of experiencing symptoms of common mental disorders. UK Biobank data links the same dietary pattern to an increased risk of dementia. In the REGARDS cohort, a 10% increase in the relative intake of ultra-processed foods was associated with a 16% increase in the risk of cognitive impairment and an 8% increase in the risk of stroke, independent of adherence to the Mediterranean, DASH, or MIND dietary patterns.
“The boundary between physical health and mental health has always been more administrative than biological,” says Perspective co-author Dr. Nicholas Fabiano of the Department of Psychiatry at the University of Ottawa. “Microplastics don’t respect that boundary. The same particles that clog atheroma also reach the brain. The same dietary exposures that increase cardiovascular risk also increase the risk of depression and dementia. We’re looking at one problem that has many clinical aspects.”
In this perspective, removal is treated as the next frontier rather than a distant aspiration. Bornstein and colleagues at the Karl-Gustav Karls University Hospital in Dresden recently reported that therapeutic apheresis can extract substances consistent with microplastic particles from human plasma. This mechanism is biologically plausible. Clinical infrastructure already exists in tertiary centers around the world. Based on current evidence, apheresis is the most promising intervention candidate the field has produced.
“We were initially surprised by what we observed,” says senior co-author Dr. Stefan R. Bornstein of the Dresden University of Technology and King’s College London. “Apheresis is a well-established clinical modality. The fact that it appears to engage these particles in vivo opens avenues that did not exist a year ago. The current work is to validate the signal against metrics that the broader scientific community can agree on and develop scalable alternatives to suit polymer specificity, tissue compartments, and patient populations.”
“What is still missing in this field is a measurement infrastructure that can rank polymers by harm and confirm that interventions are working,” added co-author Dr. Charlotte Steenbrock, also from the Dresden University of Technology. “Without validated, reproducible, polymer-specific quantification, we cannot confirm the removal strategy in the strict sense of the word. This is not a weakness of the apheresis approach; it is a hallmark of a field that is working ahead of proprietary analytical tools.”
The authors note that the science of brain health is now moving toward subtraction at the level of national funding priorities with the same seriousness with which it has long focused on addition. In April 2026, ARPA-H, an institution built on the model that created the fundamental research behind GPS, the early internet, and mRNA vaccines, launched STOMP: Systematic Targeting Of MicroPlastics. The program is organized around the same three priorities identified in the New Perspective. The aim is to develop measurements that can characterize nanoscale particles in complex biological tissues, to understand the mechanisms by which microplastics pass through organs and cause harm, and to apply that knowledge to clinical removal.
Vulnerable people are at the center of policy issues. Microplastics are localized within the intracellular compartment of the human placenta, suggesting that they are exposed to the fetus during the most critical period of neural development. Children have a well-developed blood-brain barrier and consume more per kilogram than adults, resulting in lifelong burden trajectories that are unpredictable in today’s adult cohorts. Patients suffering from cerebrovascular diseases for which the Marfera signal is most clinically relevant are already attending clinics today. Nihardt’s finding that patients with neurodegenerative diseases also have a disproportionately high burden on the brain raises the persistent question of whether these particles are passengers, accelerators, or contributors.
In the absence of validated clinical elimination measures, population-wide exposure reduction is currently only achievable by reducing consumption of ultra-processed foods, the Observatory notes. It’s not a trivial intervention. But it is the only tool the field currently has that works according to the scale of the problem.
